Foundation Resource Management Inc. lessened its position in shares of Pfizer Inc. (NYSE:PFE) by 2.7% during the second quarter, according to its most recent filing with the Securities and Exchange Commission. The firm owned 400,567 shares of the biopharmaceutical company’s stock after selling 11,021 shares during the period. Pfizer makes up about 4.0% of Foundation Resource Management Inc.’s holdings, making the stock its 9th biggest position. Foundation Resource Management Inc.’s holdings in Pfizer were worth $13,099,000 at the end of the most recent reporting period.
A number of other institutional investors have also recently bought and sold shares of the stock. Reik & CO. LLC boosted its stake in shares of Pfizer by 1.4% in the 1st quarter. Reik & CO. LLC now owns 19,160 shares of the biopharmaceutical company’s stock valued at $625,000 after purchasing an additional 265 shares in the last quarter. Windsor Capital Management LLC raised its holdings in Pfizer by 1.6% during the 1st quarter. Windsor Capital Management LLC now owns 17,991 shares of the biopharmaceutical company’s stock valued at $587,000 after buying an additional 276 shares during the last quarter. GYL Financial Synergies LLC raised its holdings in Pfizer by 0.9% during the 1st quarter. GYL Financial Synergies LLC now owns 30,718 shares of the biopharmaceutical company’s stock valued at $1,003,000 after buying an additional 283 shares during the last quarter. Gilbert & Cook Inc. raised its holdings in Pfizer by 3.0% during the 1st quarter. Gilbert & Cook Inc. now owns 9,794 shares of the biopharmaceutical company’s stock valued at $320,000 after buying an additional 285 shares during the last quarter. Finally, Bridgeworth LLC raised its holdings in Pfizer by 1.6% during the 1st quarter. Bridgeworth LLC now owns 18,280 shares of the biopharmaceutical company’s stock valued at $597,000 after buying an additional 289 shares during the last quarter. 70.28% of the stock is currently owned by institutional investors and hedge funds.
NYSE PFE traded down $0.36 on Wednesday, reaching $33.67. 685,864 shares of the stock were exchanged, compared to its average volume of 33,425,040. Pfizer Inc. has a one year low of $27.88 and a one year high of $44.10. The firm has a market capitalization of $189.03 billion, a PE ratio of 12.01, a PEG ratio of 2.70 and a beta of 0.68. The company’s 50-day simple moving average is $35.11 and its two-hundred day simple moving average is $36.13. The company has a current ratio of 1.02, a quick ratio of 0.78 and a debt-to-equity ratio of 0.56.
Pfizer (NYSE:PFE) last released its earnings results on Tuesday, April 28th. The biopharmaceutical company reported $0.80 EPS for the quarter, topping analysts’ consensus estimates of $0.71 by $0.09. The company had revenue of $12.03 billion for the quarter, compared to analysts’ expectations of $11.38 billion. Pfizer had a net margin of 31.17% and a return on equity of 25.76%. The firm’s revenue was down 8.3% compared to the same quarter last year. During the same quarter last year, the business earned $0.85 EPS. Sell-side analysts forecast that Pfizer Inc. will post 2.88 earnings per share for the current fiscal year.
The business also recently announced a quarterly dividend, which will be paid on Tuesday, September 1st. Stockholders of record on Friday, July 31st will be paid a dividend of $0.38 per share. This represents a $1.52 dividend on an annualized basis and a dividend yield of 4.51%. The ex-dividend date of this dividend is Thursday, July 30th. Pfizer’s dividend payout ratio is currently 51.53%.
Several research analysts have commented on PFE shares. JPMorgan Chase & Co. decreased their price objective on shares of Pfizer from $37.00 to $36.00 and set a “neutral” rating for the company in a report on Monday, June 1st. Zacks Investment Research lowered shares of Pfizer from a “buy” rating to a “hold” rating and set a $40.00 price objective for the company. in a report on Monday, May 4th. TheStreet upgraded shares of Pfizer from a “c+” rating to a “b” rating in a research note on Monday, June 1st. Mizuho assumed coverage on shares of Pfizer in a research note on Monday, June 29th. They issued a “buy” rating and a $38.00 price target for the company. Finally, SVB Leerink began coverage on shares of Pfizer in a research note on Tuesday, June 16th. They issued a “market perform” rating and a $40.00 price target for the company. Ten research analysts have rated the stock with a hold rating and four have issued a buy rating to the stock. The stock currently has a consensus rating of “Hold” and a consensus price target of $38.72.
In related news, EVP Douglas M. Lankler sold 65,000 shares of Pfizer stock in a transaction dated Wednesday, April 29th. The stock was sold at an average price of $37.85, for a total value of $2,460,250.00. Following the completion of the sale, the executive vice president now directly owns 135,375 shares in the company, valued at $5,123,943.75. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, SVP Jennifer B. Damico sold 2,181 shares of Pfizer stock in a transaction dated Friday, June 5th. The shares were sold at an average price of $36.13, for a total value of $78,799.53. Following the completion of the sale, the senior vice president now owns 7,542 shares of the company’s stock, valued at $272,492.46. The disclosure for this sale can be found here. Insiders have sold 69,362 shares of company stock valued at $2,622,691 over the last three months. Insiders own 0.08% of the company’s stock.
Pfizer Inc discovers, develops, manufactures, and sells healthcare products worldwide. It offers medicines and vaccines in various therapeutic areas, including internal medicine, vaccines, oncology, inflammation and immunology, and rare diseases under the Lyrica, Chantix/Champix, Eliquis, Ibrance, Sutent, Xalkori, Inlyta, Xtandi, Enbrel, Xeljanz, Eucrisa, BeneFix, Genotropin, and Refacto AF/Xyntha brands.
Want to see what other hedge funds are holding PFE? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Pfizer Inc. (NYSE:PFE).
Receive News & Ratings for Pfizer Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pfizer and related companies with MarketBeat.com's FREE daily email newsletter.